Welcome to our dedicated page for Immunome SEC filings (Ticker: IMNM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Immunome, Inc. (IMNM) SEC filings page on Stock Titan provides direct access to the company’s U.S. Securities and Exchange Commission disclosures, including Form 8-K current reports and other registered offerings. These documents are central for understanding how a clinical-stage targeted oncology company like Immunome describes its pipeline, clinical data and capital raising activities to regulators and investors.
Immunome’s recent Form 8-K filings cover several important topics. One 8-K details positive topline results from the global pivotal Phase 3 RINGSIDE trial of varegacestat, the company’s investigational oral gamma secretase inhibitor for progressing desmoid tumors, including the primary endpoint in progression-free survival and key secondary endpoints. The same filing discusses safety findings and the company’s stated plan to submit a New Drug Application for varegacestat to the U.S. Food and Drug Administration.
Other 8-Ks address financial and capital markets events, such as a follow-on public offering of common stock under an effective shelf registration statement on Form S-3, including the number of shares, public offering price and underwriters. Additional current reports reference quarterly financial results, business updates, and the furnishing of investor presentations that describe Immunome’s pipeline, including IM-1021, IM-3050 and preclinical ADC programs built around the HC74 TOP1 inhibitor payload.
Through this page, users can review how Immunome characterizes the design and potential attributes of its HC74 payload, summarizes preclinical data, and outlines risks and forward-looking statements in its regulatory language. Stock Titan enhances access to these filings with AI-powered summaries that highlight key points from lengthy documents, helping readers quickly identify clinical milestones, financing terms, and strategic disclosures without manually parsing every section.
Immunome Inc. director Philip Wagenheim sold shares of Common Stock in two open-market transactions. He sold 36,800 shares on March 20, 2026 at a weighted average price of $20.47 per share and 28,200 shares on March 23, 2026 at a weighted average price of $20.65 per share. After these sales, he directly owns 341,147 shares of Immunome Common Stock.
Immunome Inc. director Jean Jacques Bienaimé reported open-market purchases of the company’s common stock. On March 10, 2026, he bought 1,000 shares at $22.12 per share, followed by another 1,000 shares at $21.55 per share on March 11, 2026. After these total purchases of 2,000 shares, he directly owns 38,415 shares of Immunome common stock.
Immunome, Inc. (IMNM) is an oncology-focused biotechnology company developing antibody‑drug conjugates (ADCs) and radioligand therapies. Its lead program, varegacestat, showed positive topline Phase 3 RINGSIDE results in desmoid tumors, including an 84% reduction in risk of progression or death versus placebo and a 56% objective response rate compared with 9% on placebo. The company plans to submit a new drug application for varegacestat in the second quarter of 2026.
Additional programs include IM‑1021, a ROR1‑targeted ADC in Phase 1 with observed objective responses in B‑cell lymphomas, and IM‑3050, a FAP‑targeted lutetium‑177 radioligand therapy with Phase 1 initiation planned in early 2026. Three preclinical solid‑tumor ADCs (IM‑1617, IM‑1340, IM‑1335) have IND‑enabling work underway with anticipated 2026 submissions. Immunome has expanded its pipeline through transactions with Ayala, Zentalis, BMS and Purdue Research Foundation, and reported an approximate non‑affiliate market value of $728.5 million as of June 30, 2025, with 113,133,199 common shares outstanding as of February 27, 2026.
Immunome, Inc. reported full-year 2025 results and highlighted major progress across its oncology pipeline. The company posted a net loss of $212.4 million, improving from $293.0 million in 2024, on collaboration revenue of $6.9 million. Research and development expenses were $177.3 million and general and administrative expenses were $43.8 million, both reflecting higher investment and share-based compensation.
Immunome ended 2025 with cash and cash equivalents of $653.5 million, boosted by a December underwritten public offering that raised $460.5 million in gross proceeds. Management expects this cash position to fund operations into 2028.
Clinically, the Phase 3 RINGSIDE trial of varegacestat in desmoid tumors met its primary endpoint with an 84% reduction in risk of progression or death (hazard ratio 0.16, p<0.0001) and a 56% objective response rate versus 9% on placebo. Immunome plans a New Drug Application submission in the second quarter of 2026, while also advancing IM-1021, IM-3050 and multiple early-stage ADC programs toward key 2026 milestones.
Immunome, Inc. reported that investment adviser Redmile Group, LLC and its principal Jeremy C. Green beneficially own 5,718,385 shares of Immunome common stock. This stake represents 5.2% of the outstanding common shares.
The shares are held by private investment funds managed by Redmile, with Redmile and Green having shared voting and shared dispositive power over all 5,718,385 shares and no sole voting or dispositive power. The percentage is calculated using 91,710,277 shares outstanding as of November 3, 2025, plus 18,625,000 shares issued and sold as of December 18, 2025.
Redmile and Green state that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Immunome. They each disclaim beneficial ownership beyond any pecuniary interest.
Immunome, Inc.'s president and CEO, who is also a director, reported buying additional company stock. On 12/18/2025, the reporting person purchased 46,511 shares of Immunome common stock at a price of $21.5 per share in an open-market style purchase that occurred in connection with the company’s recently completed underwritten public offering of common stock.
Following this transaction, the reporting person beneficially owns 853,247 shares of Immunome common stock held directly. The filing is made on behalf of a single reporting person and reflects a straightforward increase in their direct ownership stake.
Immunome, Inc. is conducting a follow-on public offering of 18,625,000 shares of common stock at $21.50 per share, for expected gross proceeds of approximately $400 million before underwriting discounts, commissions and expenses. All shares are being sold by the company, and the closing is expected on December 18, 2025, subject to customary conditions. The underwriting syndicate is led by Leerink Partners, J.P. Morgan, TD Securities (USA), Goldman Sachs & Co. and Guggenheim Securities, and they have a 30-day option to buy up to an additional 2,793,750 shares at the public offering price, less underwriting discounts and commissions.
Immunome reported positive topline results from its global Phase 3 RINGSIDE trial of varegacestat, an oral, once-daily gamma secretase inhibitor, in patients with progressing desmoid tumors.
The study met its primary endpoint of progression-free survival, cutting the risk of disease progression or death by 84% vs placebo (hazard ratio 0.16; 95% CI 0.071–0.375; p<0.0001). Confirmed objective response rate was 56% with varegacestat versus 9% with placebo, and median best tumor volume change was -83% vs +11% with placebo. All key secondary endpoints, including landmark tumor volume reduction and worst pain intensity, showed statistically significant benefits. Varegacestat was generally well tolerated, though diarrhea, fatigue, rash, nausea and cough were common, and about 55.6% of premenopausal women experienced ovarian toxicity. Immunome plans to present additional RINGSIDE data and submit a New Drug Application to the U.S. Food and Drug Administration in Q2 2026. The company also highlighted preclinical data suggesting its HC74 TOP1 inhibitor ADC payload may offer advantages over existing TOP1 inhibitor payloads.
Immunome reported positive topline results from its global Phase 3 RINGSIDE trial of varegacestat, an oral, once-daily gamma secretase inhibitor, in patients with progressing desmoid tumors.
The study met its primary endpoint of progression-free survival, cutting the risk of disease progression or death by 84% vs placebo (hazard ratio 0.16; 95% CI 0.071–0.375; p<0.0001). Confirmed objective response rate was 56% with varegacestat versus 9% with placebo, and median best tumor volume change was -83% vs +11% with placebo. All key secondary endpoints, including landmark tumor volume reduction and worst pain intensity, showed statistically significant benefits. Varegacestat was generally well tolerated, though diarrhea, fatigue, rash, nausea and cough were common, and about 55.6% of premenopausal women experienced ovarian toxicity. Immunome plans to present additional RINGSIDE data and submit a New Drug Application to the U.S. Food and Drug Administration in Q2 2026. The company also highlighted preclinical data suggesting its HC74 TOP1 inhibitor ADC payload may offer advantages over existing TOP1 inhibitor payloads.
Immunome, Inc. is offering $400,000,000 of its common stock in a public follow-on offering, and has granted underwriters a 30-day option to purchase up to an additional $60,000,000 of shares at the public offering price, less underwriting discounts and commissions.
The company plans to use the net proceeds, together with existing cash and cash equivalents, to fund the potential commercial launch of varegacestat for desmoid tumors, expand commercial development and manufacturing scale-up for varegacestat, advance clinical and preclinical oncology programs, and for working capital and general corporate purposes. A portion may also be used to in-license, acquire or invest in additional complementary businesses, technologies, products or assets.
As of September 30, 2025, Immunome had 91,706,948 shares of common stock outstanding and historical net tangible book value of $263.9 million, or $2.88 per share. Management estimates that existing cash and cash equivalents, together with the estimated net proceeds from this offering, will be sufficient to fund projected operations into 2028, though buyers face risks such as immediate and future dilution, share price volatility, an existing at-the-market program with $134.1 million capacity remaining, and the company’s intention not to pay cash dividends for the foreseeable future.
Immunome, Inc. is offering $400,000,000 of its common stock in a public follow-on offering, and has granted underwriters a 30-day option to purchase up to an additional $60,000,000 of shares at the public offering price, less underwriting discounts and commissions.
The company plans to use the net proceeds, together with existing cash and cash equivalents, to fund the potential commercial launch of varegacestat for desmoid tumors, expand commercial development and manufacturing scale-up for varegacestat, advance clinical and preclinical oncology programs, and for working capital and general corporate purposes. A portion may also be used to in-license, acquire or invest in additional complementary businesses, technologies, products or assets.
As of September 30, 2025, Immunome had 91,706,948 shares of common stock outstanding and historical net tangible book value of $263.9 million, or $2.88 per share. Management estimates that existing cash and cash equivalents, together with the estimated net proceeds from this offering, will be sufficient to fund projected operations into 2028, though buyers face risks such as immediate and future dilution, share price volatility, an existing at-the-market program with $134.1 million capacity remaining, and the company’s intention not to pay cash dividends for the foreseeable future.